Skip to content

Exploration of Pathogenesis and therapeutic targets for Penile caner and Urethral cancer, and Investigation of Antitumor Effects and Mechanisms in In Vivo Animal Models, In Vitro Organoids, and Cell Line Models

Exploration of Pathogenesis and therapeutic targets for Penile caner and Urethral cancer, and Investigation of Antitumor Effects and Mechanisms in In Vivo Animal Models, In Vitro Organoids, and Cell Line Models

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500105390
Enrollment
Unknown
Registered
2025-07-02
Start date
2025-05-29
Completion date
Unknown
Last updated
2025-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Penile cancer, urethral cancer

Interventions

Patients with penile or urethral tumors:None
Patients with urethral stricture, circumcision or phimosis:None

Sponsors

Shanghai Sixth People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Male patients; 2. Aged 18 years or above (non-vulnerable groups); 3. Patients must be able to complete relevant questionnaires under the guidance of medical staff; 4. patients attending the clinic for proposed surgical treatment due to circumcision, prepuce, urethral stenosis, common urological tumours (renal tumours, prostate tumours, urogenital tumours); 5. Patients with penile cancer and urethral cancer who consult the doctor for proposed surgical treatment due to penile swelling, perineal swelling, perineal abscess and scrotal swelling; 6. Patients without serious cardiovascular and cerebrovascular diseases, hepatic and renal insufficiency, haematological system diseases and other patients who are considered unsuitable for chemotherapy by clinicians.

Exclusion criteria

Exclusion criteria: The test group does not meet the diagnostic criteria for penile or urethral cancer, as determined by clinical or pathological examination. The principal investigator or treating physician considers other reasons to be unsuitable for clinical research subjects.

Design outcomes

Primary

MeasureTime frame
Progression Free Survival;

Secondary

MeasureTime frame
Objective Response Rate;Overall Survival;Drug sensitivity;AEs;Genotyping;Tumor volume and maximum diameter;Key regulatory factors;PDX model tumorigenicity;

Countries

China

Contacts

Public ContactLujie Song

Shanghai Sixth People’s Hospital

ljsong@sjtu.edu.cn+86 189 3017 2157

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026